TY - JOUR
T1 - 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer
T2 - evidence from the Breast Cancer Association Consortium
AU - Warren, Helen
AU - Dudbridge, Frank
AU - Fletcher, Olivia
AU - Orr, Nick
AU - Johnson, Nichola
AU - Hopper, John L
AU - Apicella, Carmel
AU - Southey, Melissa C
AU - Mahmoodi, Maryam
AU - Schmidt, Marjanka K
AU - Broeks, Annegien
AU - Cornelissen, Sten
AU - Braaf, Linda M
AU - Muir, Kenneth R
AU - Lophatananon, Artitaya
AU - Chaiwerawattana, Arkom
AU - Wiangnon, Surapon
AU - Fasching, Peter A
AU - Beckmann, Matthias W
AU - Ekici, Arif B
AU - Schulz-Wendtland, Ruediger
AU - Sawyer, Elinor J
AU - Tomlinson, Ian
AU - Kerin, Michael
AU - Burwinkel, Barbara
AU - Marme, Frederik
AU - Schneeweiss, Andreas
AU - Sohn, Christof
AU - Guénel, Pascal
AU - Truong, Thérèse
AU - Laurent-Puig, Pierre
AU - Mulot, Claire
AU - Bojesen, Stig E
AU - Nielsen, Sune F
AU - Flyger, Henrik
AU - Nordestgaard, Børge G
AU - Milne, Roger L
AU - Benítez, Javier
AU - Arias-Pérez, José-Ignacio
AU - Zamora, M Pilar
AU - Anton-Culver, Hoda
AU - Ziogas, Argyrios
AU - Bernstein, Leslie
AU - Dur, Christina Clarke
AU - Brenner, Hermann
AU - Müller, Heiko
AU - Arndt, Volker
AU - Langheinz, Anne
AU - Meindl, Alfons
AU - Golatta, Michael
AU - GENICA Network
N1 - 2012 AACR
PY - 2012/10
Y1 - 2012/10
N2 - BACKGROUND: Our recent genome-wide association study identified a novel breast cancer susceptibility locus at 9q31.2 (rs865686).METHODS: To further investigate the rs865686-breast cancer association, we conducted a replication study within the Breast Cancer Association Consortium, which comprises 37 case-control studies (48,394 cases, 50,836 controls).RESULTS: This replication study provides additional strong evidence of an inverse association between rs865686 and breast cancer risk [study-adjusted per G-allele OR, 0.90; 95% confidence interval (CI), 0.88; 0.91, P = 2.01 × 10(-29)] among women of European ancestry. There were ethnic differences in the estimated minor (G)-allele frequency among controls [0.09, 0.30, and 0.38 among, respectively, Asians, Eastern Europeans, and other Europeans; P for heterogeneity (P(het)) = 1.3 × 10(-143)], but no evidence of ethnic differences in per allele OR (P(het) = 0.43). rs865686 was associated with estrogen receptor-positive (ER(+)) disease (per G-allele OR, 0.89; 95% CI, 0.86-0.91; P = 3.13 × 10(-22)) but less strongly, if at all, with ER-negative (ER(-)) disease (OR, 0.98; 95% CI, 0.94-1.02; P = 0.26; P(het) = 1.16 × 10(-6)), with no evidence of independent heterogeneity by progesterone receptor or HER2 status. The strength of the breast cancer association decreased with increasing age at diagnosis, with case-only analysis showing a trend in the number of copies of the G allele with increasing age at diagnosis (P for linear trend = 0.0095), but only among women with ER(+) tumors.CONCLUSIONS: This study is the first to show that rs865686 is a susceptibility marker for ER(+) breast cancer.IMPACT: The findings further support the view that genetic susceptibility varies according to tumor subtype.
AB - BACKGROUND: Our recent genome-wide association study identified a novel breast cancer susceptibility locus at 9q31.2 (rs865686).METHODS: To further investigate the rs865686-breast cancer association, we conducted a replication study within the Breast Cancer Association Consortium, which comprises 37 case-control studies (48,394 cases, 50,836 controls).RESULTS: This replication study provides additional strong evidence of an inverse association between rs865686 and breast cancer risk [study-adjusted per G-allele OR, 0.90; 95% confidence interval (CI), 0.88; 0.91, P = 2.01 × 10(-29)] among women of European ancestry. There were ethnic differences in the estimated minor (G)-allele frequency among controls [0.09, 0.30, and 0.38 among, respectively, Asians, Eastern Europeans, and other Europeans; P for heterogeneity (P(het)) = 1.3 × 10(-143)], but no evidence of ethnic differences in per allele OR (P(het) = 0.43). rs865686 was associated with estrogen receptor-positive (ER(+)) disease (per G-allele OR, 0.89; 95% CI, 0.86-0.91; P = 3.13 × 10(-22)) but less strongly, if at all, with ER-negative (ER(-)) disease (OR, 0.98; 95% CI, 0.94-1.02; P = 0.26; P(het) = 1.16 × 10(-6)), with no evidence of independent heterogeneity by progesterone receptor or HER2 status. The strength of the breast cancer association decreased with increasing age at diagnosis, with case-only analysis showing a trend in the number of copies of the G allele with increasing age at diagnosis (P for linear trend = 0.0095), but only among women with ER(+) tumors.CONCLUSIONS: This study is the first to show that rs865686 is a susceptibility marker for ER(+) breast cancer.IMPACT: The findings further support the view that genetic susceptibility varies according to tumor subtype.
KW - Aged
KW - Breast Neoplasms
KW - Case-Control Studies
KW - Chromosome Mapping
KW - Chromosomes, Human, Pair 9
KW - Female
KW - Genetic Predisposition to Disease
KW - Genome-Wide Association Study
KW - Humans
KW - Middle Aged
KW - Polymorphism, Single Nucleotide
KW - Receptors, Estrogen
KW - Receptors, Progesterone
KW - Journal Article
KW - Research Support, N.I.H., Extramural
KW - Research Support, Non-U.S. Gov't
KW - Research Support, U.S. Gov't, Non-P.H.S.
U2 - 10.1158/1055-9965.EPI-12-0526
DO - 10.1158/1055-9965.EPI-12-0526
M3 - Article
C2 - 22859399
SN - 1055-9965
VL - 21
SP - 1783
EP - 1791
JO - Cancer Epidemiology Biomarkers & Prevention
JF - Cancer Epidemiology Biomarkers & Prevention
IS - 10
ER -